Highlights d 3 Å cryo-EM structure of the CB1-G i complex bound to potent agonist MDMB-Fubinaca d MDMB-Fubinaca locks ''toggle switch'' residues F200 3.36 / W356 6.48 in active conformation d Quantum mechanics calculations reveal the mechanism for the high affinity of Fubinaca d Molecular dynamic simulations reveal a path for ligand entry between TM1 and TM7
INTRODUCTION
The cannabinoid receptor 1 (CB1) is the most abundantly expressed G protein-coupled receptor (GPCR) in the brain (Marsicano and Lutz, 1999) and the target for D 9 -tetrahydrocannabinol (D 9 -THC), the major psychoactive component of Cannabis that has been used for recreational and therapeutic purposes for millennia. Recently, CB1 has been targeted by designed synthetic cannabinoids which, like their plant-based counterparts, piggyback their pharmacology on a collection of endogenous molecules known as the endocannabinoids. Endocannabinoid signaling has proven to play important roles in memory, mood, sleep, appetite, inflammation, and pain sensation (Mackie, 2006) , thereby rendering CB1 an attractive target for the development of novel therapeutics toward a variety of conditions. CB1 elicits its physiological responses by coupling primarily to G i/o proteins to inhibit adenylate cyclase and cyclic AMP signaling, although coupling with G s or G q/11 has also been reported (Glass and Felder, 1997; Lauckner et al., 2005) . Activation of CB1 has been shown to have anxiolytic, analgesic, neuroprotective, and anti-nausea effects (Campos et al., 2012; Izzo et al., 2009; Micale et al., 2013) , while preclinical data indicate that D 9 -THC and synthetic cannabinoid agonists are effective antinociceptive agents in laboratory animal models of neurodegenerative, neuroinflammatory, and pain-related disease states (Fagan and Campbell, 2014; Guindon and Hohmann, 2009; Pryce and Baker, 2012) . However, D 9 -THC and, to a much greater extent, synthetic cannabinoids can induce side effects that include dependence, memory impairment, hallucinations, panic attacks, seizures, convulsions, and psychoses (Cooper, 2016) . Fubinacas, a class of potent synthetic agonists infused in illicit herbal mixes such as ''K2'' or ''Spice,'' have been named ''zombie drugs'' due to their association with users in semi-comatose state (Adams et al., 2017) . Although side effects and potential lethality limit their direct therapeutic use, such compounds represent important tools to dissect mechanistic questions regarding the extent of CB1 activation and potency of distinct classes of ligands in order to design drugs with improved pharmaceutical properties.
MDMB-Fubinaca (FUB), a derivatization of the AB-Fubinaca originally developed by Pfizer, has been designated as the deadliest cannabino-mimetic sold to date (Adams et al., 2017) . A recent study on 43 synthetic cannabinoids found FUB to have the highest affinity to CB1 in a radioligand binding assay with K i values of 98 pM (Schoeder et al., 2018) . In GTPgS binding assay FUB was found to be 20-fold more potent compared to D 9 -THC (Gamage et al., 2018) . Although toxicity of FUB consumption has not been determined directly, Fubinacas have been linked to thousands of hospitalizations and numerous fatalities (Adams et al., 2017; Peace et al., 2017) . While synthetic cannabinoids have been shown to have multiple targets, they predominantly signal through CB1. To gain structural insights into the binding and activation of CB1 by FUB, we determined a 3 Å cryo-EM structure of FUB-activated full-length CB1 in complex with its down-stream heterotrimeric G i protein. The structure, complemented by molecular dynamics (MD) and ligand docking calculations, provides a snapshot into the FUB binding properties, its activation of CB1, and the structural basis of G protein coupling. This work sets the framework to integrate a large body of structure-activity relationship (SAR) studies toward understanding cannabinoid receptor activation by different classes of ligands and also provides insights into the promiscuous coupling of CB1 to both G s and G i .
RESULTS AND DISCUSSION
Cryo-EM of the CB1-FUB-G i Complex In our preliminary studies, we evaluated 10 synthetic cannabinoids for their ability to activate G i signaling ( Figure 1A ). Through GTP turnover and fluorescence-detection size exclusion chromatography (F-SEC) assays ( Figures 1B and S1A) we observed a direct correlation between complex stability and ligand ability to induce signaling. In these assays, FUB demonstrated high efficacy and complex stability ( Figure 1B) .
In addition, we prepared the CB1-FUB-G i complex in the presence of ZCZ-011 (ZCZ), a positive allosteric modulator (PAM) that was shown to mediate analgesia with no psychoactive effect (Ignatowska-Jankowska et al., 2015) . ZCZ further increased the rate of GTP turnover of FUB-bound CB1 confirming positive allosteric modulation ( Figure 1C ). However, while negative stain EM analysis (Peisley and Skiniotis, 2015) showed an intact CB1-G i complex, inspection of cryo-EM samples indicated sample dissociation, presumably due to adverse effects during cryogrid preparation (Noble et al., 2018) . To further enhance complex stability, we utilized scFv16, a single-chain variable fragment that we recently employed to obtain the cryo-EM structure of the m-opioid receptor (mOR)-G i complex . ScFv16 is derived from a monoclonal antibody that was raised against a rhodopsin:G i 1 complex. It confers GTPgS resistance to receptor-G i/o complexes, thus enhancing their stability . We thus obtained cryo-EM images of the CB1-FUB-G i -scFv16 complex and used $177,000 projections to calculate a 3D reconstruction with a global nominal resolution of 3 Å (Figures 2, S1B, S1C, and S2). Local resolution calculations indicate a range of 2.7-3.6 Å in most map regions, with the highest resolution observed at the core of the G i protein (Figure S2C) . This map enabled the building of a model for the fully activated CB1 signaling complex (Figures 2 and S2; Table S1 ).
The cryo-EM map shows well-defined density for FUB in the orthosteric binding pocket (Figures 3A and S2D) but no observable density to accommodate ZCZ. This might suggest that the PAM engages a flexible site of the receptor, although we cannot exclude the possibility that it may have dissociated from the complex during cryo-EM specimen preparation. The FUB binding pocket is composed of residues in TM2-TM3 and TM5-TM7, overlapping with the orthosteric site observed in previously reported crystal structures of active CB1 (Hua et al., 2017) (Figures 3B and 4) . Compared to other GPCRs (with the exception of rhodopsin), the FUB pocket is further buried in the TM region and is capped by ECL2, which folds into the pocket with F268 ECL2 making direct hydrophobic contacts with the ligand. FUB fits well in the map density where the indazole ring is well-identified, and the p-fluoro-benzyl and tert-butyl-ester moieties fit into the remaining density ( Figure S2D ). Furthermore, molecular dynamics (MD) simulations of several computationally docked poses converged to nearly identical ensembles that agreed well with the EM density ( Figure S2E ). The polar ester group often formed water-mediated interactions with residues on TM2 and Blue, CB1; orange, FUB; yellow, Ga i ; cyan, Gb; dark magenta, Gg; pink, scFv16. (F) Snapshot of model versus map density in the region where the scFv16 is engaging Ga i and Gb. The zoomed in region corresponds to the area highlighted by a dashed black box in (E). See also Figures S1 and S2 and Tables S1 and S3. TM7, and the tert-butyl group remained more proximal to TM2 and TM3.
CB1 Activation by FUB
Compared to the inverse agonist (taranabant)-and antagonist (AM-6538)-bound structures of CB1 (Hua et al., 2016; Shao et al., 2016) , the ligand binding pocket in FUB-bound CB1 undergoes an extensive structural rearrangement that agrees well with that observed in the agonist-bound CB1 structures (Hua et al., 2017) . This structural rearrangement involves the inward displacement of TM1 and TM2, along with the displacement of the N terminus out of the transmembrane core ( Figure 4 ). Such large differences in the binding pocket between active and inactive states have not been observed in other GPCRs; rootmean-square deviation (RMSD) values between binding pocket residues in the active and inactive states range between 2.7 Å in the b 2 -adrenergic receptor (b 2 AR) and 5.1 Å in the mOR compared to 8.5 Å in CB1. The TM2 movement is accompanied by the repositioning of residues F170 2.5 , F174 2.61 , F177 2.64 , and H178 2.65 (superscripts indicate Ballesteros-Weinstein numbering for GPCRs) (Ballesteros and Weinstein, 1995) , that turn toward the pocket in the active conformation and contribute to interactions with the agonist ( Figure 4A ). Notably, F200 3.36 , which in the inactive receptor state is stabilized by interactions with W356 6.48 , rotates away to interact with the indazole ring of FUB ( Figures 4A and 4B ). The role of the interaction between F200 3.36 and W356 6.48 , also known as the ''toggle twin switch,'' in stabilizing the inactive conformation of CB1 was previously demonstrated by mutation of F 3.36 A, which resulted in high basal activity in a GTPgS binding assay (McAllister et al., 2004) . In our structure, the F200 3.36 repositioning allows W356 6.48 to rotate inward, resulting in the relaxation of the kink at the highly conserved P358 6.50 , with a consequent straightening and an outward movement of the cytoplasmic end of TM6 that serves to create a cavity for G protein binding ( Figure 4B ). Furthermore, the structural rearrangements to accommodate the agonist involve the displacement of the receptor N terminus, a region which along the proceeding TM1 helix has limited resolution in our map ($4 Å ). These observations suggest that these elements are relatively mobile, consistent with their dynamics observed in MD simulations ( Figure S3A ). It is clear, however, that the N-terminal displacement is necessary to accommodate the agonist, due to steric clash with the tert-butyl moiety in FUB or the terpenoid scaffold in the previously reported CB1 agonists AM-11542 and AM-841 ( Figure 4C ). This steric clash is not present in the CB1 structures bound to antagonists or inverse agonists reported to date (Hua et al., 2016; Shao et al., 2016) , raising the possibility that the N-terminal displacement may be part of the activation mechanism. Indeed, in all MD simulations performed here, the N terminus regularly fluctuated between contacting the extracellular surface of the receptor and residing in the bulk solvent ( Figure S3A ).
The MD simulations further hint at a possible mechanism for ligand entry at the CB1 receptor. In four out of six simulations, TM1 moves outward to create a gap between TM1 and TM7 ( Figure S3A ). This small opening is similar to one observed in the lipid bilayer between TM1 and TM7 in an inactive-state structure ( Figure S3B ) and has been proposed to facilitate ligand entry and dissociation in CB1 and all lipid-activated receptors (Shao et al., 2016) . Intriguingly, the simulations also show that the opening of the TM1-TM7 gap coincides with both the binding of a lipid molecule (POPC) and the stabilization of the upward position of the N terminus relative to the extracellular surface of the receptor ( Figures S3C-S3F ).
FUB Binding and Comparison with Other CB1 Agonists
Crystal structures of CB1 constructs truncated at N and C termini have been previously determined in complex with agonists AM-11542 and AM-841 that possess a THC-like scaffold and are structurally distinct from FUB (Hua et al., 2017) . Despite the differences in chemical composition, FUB assumes the same overall C-shape geometry as AM-11542 and AM-841, with overlapping ligand binding pockets ( Figures 4B and S4 ). The p-fluorobenzyl that p-p stacks with W279 5.43 , and the indazole group of FUB engage in hydrophobic interactions with aromatic residues in TM5 and TM6 ( Figure 4A ). Notably, the C3 alkyl chain of the AM-derivatives and the p-fluorobenzyl of FUB occupy the same position in a narrow side pocket comprised of residues in TM3, TM5, TM6, and ECL2 ( Figures 4B and 4C ). This pocket has been observed to be occupied by the aliphatic chain of CB1 antagonist AM-6538 (Hua et al., 2016 ) ( Figure 4C ) and is also present in the sphingosine 1-phosphate receptor (S 1 P1) where it was shown to be occupied by the aliphatic moiety of a selective antagonist (Hanson et al., 2012) . It thus appears that the side pocket is a conserved docking region for aliphatic chains in lipid binding receptors, where it seems to be important for ligand affinity regardless of its ability to activate the receptor.
This might explain the similar affinities observed for the AMderivatives and FUB (indicated K i values are 0.098 and 0.11 nM for FUB and AM-11542, respectively) (Schoeder et al., 2018) as also supported by SAR studies showing that the replacement of the FUB p-fluorobenzyl with an alkyl chain yields a ligand with similar affinity (Schoeder et al., 2018) and EC 50 (Adams et al., 2017) . In agreement with this interpretation, our ligand docking calculations show that the aliphatic moiety of a Fubinaca derivative (5F-MDMB-Pinaca) overlaps with the p-fluorobenzyl group of FUB ( Figure S4B ). D 9 -THC has a much greater safety profile compared to synthetic cannabinoids (Fantegrossi et al., 2014) . One reason that could attribute to this toxicity difference is that D 9 -THC is a partial agonist whereas synthetic cannabinoids like FUB are full agonists (Atwood et al., 2010) . Although structurally similar to D 9 -THC, AM-11542 shows enhanced potency and efficacy for CB1 due to the addition of a 1 0 ,1 0 -gem-dimethylheptyl (GDH) chain at the C3 position. The GDH group in AM-11542 mediates hydrophobic interactions with the ''toggle twin switch,'' which undergoes concerted conformational changes upon agonistbinding and activation ( Figure 4B ). In FUB instead, strong aromatic interactions with both F200 3.36 and W356 6.48 are maintained by the indazole ring, thereby explaining the high efficacy of this ligand ( Figure 4B ). The lack of the toggle switch interaction has been suggested as the explanation of the partial agonist activity observed for D 9 -THC compared to the full agonist activity of the AM compounds. In support of this notion, our docking calculations of D 9 -THC in the CB1 cryo-EM structure yields several poses where the terpenoid ring aligns well with that of AM-11542 in the CB1 crystal structure (PDB: 5XRA) (Hua et al., 2017) , but the aliphatic moiety of D 9 -THC fluctuates between penetrating the hydrophobic cavity occupied by the p-fluorobenzyl group in FUB and a downward conformation that points toward the toggle switch to activate the receptor ( Figures S4C-S4E ). Hence, it appears that the conformational variability of D 9 -THC likely compromises both its affinity and potency for CB1, a characteristic that presumably makes it safer compared to more rigid and potent synthetic cannabinoids.
In contrast, the high efficacy of FUB is partly due to its structural rigidity in the characteristic C-shape configuration that stereotypically recognizes the CB1 binding site and stabilizes the active receptor conformation (Figures 4 and S4A ). FUB analogs demonstrate that intramolecular interactions between the heterocyclic core and the linker of the tert-butyl can significantly stabilize the bound conformation, with a marked loss of potency when the indazole core is replaced with an indole or when the amide is replaced by a ketone (Schoeder et al., 2018) . Accordingly, our quantum mechanics (QM) calculations show that the bound conformation in FUB is much lower in energy compared to the alternate conformation with a flipped dihedral angle between the amide and the indazole ( Figure S5 ). Because this intramolecular interaction is absent in less potent analogs, the energy difference between the bound and flipped pose is significantly lower, and thus these compounds display a mix of conformations compromising their activity.
The tert-butyl position in FUB, which overlaps with the terpenoid scaffold of the AM agonists, greatly diversifies in various derivatives of the Fubinaca family ( Figure 1A ). In the CB1-FUB-G i -scFv16 structure, the ester moiety of FUB is in position to form polar interactions with H178 2.65 ( Figure S4F ). In addition, molecular mechanics calculations using JAWS (Michel et al., 2009 ) consistently showed the presence of a strongly bound (>3.5 kcal/mol) water molecule in between the amide linker, H178 2.65 and S383 7.39 ( Figures S4F-S4H ). MD simulations further support the presence of a polar network involving the ligand's ester moiety, H178 2.65 and S383 7.39 , but the precise arrangement and behavior of waters tends to differ slightly from the JAWS-predicted network. Both ligand docking and (B) FUB and AM-11542 (PDB: 5XRA) bound at the CB1 orthosteric pocket make direct contacts with residues F200 3.36 and W356 6.48 . The rotation of F200 3.36 to interact with the indazole ring of FUB allows W356 6.48 to rotate outward, with a consequent outward movement of the cytoplasmic end of TM6 that serves to create a cavity for G protein binding. The groups interacting with the ''toggle twin switch'' of CB1 (indazole ring of FUB and GDH moiety of AM-11542) are marked in orange. The inactive receptor structure is shown in gray (PDB: 5TGZ). (C) A comparison of binding pockets of AM-6538 (antagonist, gray, PDB: 5TGZ), AM-11542 (agonist, cyan, PDB: 5XRA), and FUB (orange). The receptor is presented as cartoon with the active conformation in blue (present cryo-EM structure) and the inactive conformation in gray (PDB: 5TGZ). See also Figures S3, S4 , and S5. comparison to an agonist bound-crystal structure (PDB: 5XRA) reveal that AM analogs and D 9 -THC have a hydrogen bonding group able to interact with this water molecule and/or S383 7.39 . In agreement with these findings, mutagenesis of S383 7.39 decreases agonist binding (Hua et al., 2017; Kapur et al., 2007) , while SAR data with the hydrogen bonding moiety removed (-OH in terpenoid or cannabidiol scaffolds and amino-group in the FUB linker) reveal lower compound potency (Bow and Rimoldi, 2016) .
Propagation of Agonist-Stabilized Structural Changes
Excluding differences in regions that are stabilized by G i binding to the receptor, the structures of FUB-G i -bound and agonist-bound CB1 are remarkably similar (RMSD of C a is 1.2) ( Figure S6 ) despite the fact that the modified receptor construct used for determining the agonist-bound structure cannot signal (Hua et al., 2017) . This finding is in contrast to the b 2 AR and mOR (Rosenbaum et al., 2011) ; (Nygaard et al., 2013) , where agonist-binding alone, in the absence of G protein, cannot stabilize the fully extended active-state conformation of TM6. The higher propensity of CB1 to transition to an active conformation likely explains its inherently high basal activity (Seifert and Wenzel-Seifert, 2002) , a feature that has been shown to be important for modulating neuronal development (Njoo et al., 2015) .
A striking difference between CB1, as well as a number of lipid-activated receptors with most other family A GPCRs, is the absence of the conserved P 5.50 , whose insertion creates a bulge in TM5 and local unwinding between residues 5.45 and 5.48 to relieve geometric constraints and orient ligand-interacting residues to the binding pocket (Sansuk et al., 2011) ( Figure 5A ). In the b 2 AR and mOR, P 5.50 is involved in packing interactions with I 3.40 (found in 42% of class A GPCRs) and F 6.44 (found in 82% of class A GPCRs), which rearrange upon receptor activation (Figures 5A and 5B) (Huang et al., 2015) . Although in activated CB1 we observe relatively small rearrangements in the homologous corresponding residues L 5.50 , V 3.40 , and L 6.44 , the discussed structural changes in TM6 drive L 6.44 to move away from V 3.40 and L 5.50 ( Figure 5A ). Crucially, the lack of unwinding in CB1 due to the absence of a proline at position 5.50, makes TM5 a more rigid helix connecting the binding pocket to the G protein coupling domain. While this highly conserved P 5.50 has been proposed to play a key role in the activation of many family A receptors (Deupi, 2014) , the L 5.50 P mutation in the CB2 receptor disrupts signaling, indicating that a non-kinked TM5 is a prerequisite for cannabinoid receptor function (Zhou and Song, 2002) .
Structure of the CB1-G i Interface
Globally, the structure of the CB1-G i complex reveals a similar mode of interaction when compared to other G i bound receptors. However, the N terminus of a5 in the CB1-G i complex deviates from that of the G-protein in the mOR-G i and b 2 AR-G s complexes, resulting in a different relative orientation of the G protein. When aligned on the receptors, the G i in complex with CB1 is rotated along the membrane by 18 when compared to mOR-G i ( Figure 6A) . The difference is attributed to the more extensive interactions between the N terminus of the a5 helix and the extended TM5 of CB1 ( Figures 6B and 6C ), resulting in a relative configuration that is similar to a recently reported cryo-EM structure of a Rho-Gi complex (Kang et al., 2018) . Although TM5 is also extended in the b 2 AR-G s complex, it does not form strong interactions with the N terminus of the a5 helix due to the difference in G protein orientation ( Figure 6D ). Thus, the relative orientational differences between G protein and its respective receptors, as exemplified in the structures of CB1, mOR and b 2 AR complexes, is underlined by a change of interaction profiles. G i interactions with CB1 are primarily between the a5 helix of G i and ICL2, TM5, TM6, and H8 of CB1 ( Figures 6B and 6E ), while only a weak hydrophobic contact is observed between the b2-b3 loop of G i and ICL. In contrast, more extensive interactions are maintained between the ICL2 of the mOR and the aN-b1 loop of G i and between ICL2 of the b2AR and the aN-b1 loop of G s (Figures 6C, 6D, 6F, and 6G) . A complete list of contacts is shown in Table S2 .
The C terminus of the a5 helix of G i is in a similar position when bound to CB1 or mOR ( Figure 6A ), while the G i complexes overlay well with the structures of rhodopsin, adenosine receptor, A 1 (A 1 A) (Draper-Joyce et al., 2018) , and the serotonin receptor, 5HT1B (García-Nafría et al., 2018), in complex with G i . On the other hand, the C terminus of the a5 helix of G s coupled to receptors (e.g., the b 2 AR) is displaced by $6.5 Å , requiring a larger outward movement of TM6 compared to G i coupled receptors. Accordingly, TM6 repositions by 12 Å and 11.3 Å in CB1-G i and mOR-G i , respectively, compared to $14 Å in b 2 AR-G s (Figure 6A ), while an even larger outward displacement of TM6 is observed in the family B receptors in complex with G s . Given (E-G) Interactions between ICL2 of CB1 (blue) and Ga i (yellow) (E), mOR (magenta) and Ga i (wheat) (F), and b 2 AR (green) and Ga s (orange) (G). See also Figure S7 and Table S2. these findings, we postulate that the ability to accommodate the C terminus of Ga s is one of the determinants of G s coupling specificity. For CB1 to couple to G s , its TM6 would have to be able to move outward to a greater extent than that found in the CB1-G i complex. In the b 2 AR, the larger displacement of TM6 can be attributed to G 6.38 and G 6.42 . Although there are no glycine residues at similar positions of CB1, G357 6.49 in the conserved C 6.47 W 6.48 X 6.49 P 6.50 motif may add extra flexibility to TM6. It is also worth noting that the homologous amino acid at position 6.49 in CB2 is phenylalanine and in mOR is threonine, and both of these receptors couple very poorly to G s (Connor and Christie, 1999; Mnpotra et al., 2014) . Conformational memory calculations showed that the flexibility of TM6 around positions 6.49 and 6.50 was significantly greater for CB1 compared to CB2, but the flexibility was greater for CB2 with the F 6.49 G mutation compared to CB1 with the G 6.49 F mutation (Barnett-Norris et al., 2002) .
Role of CB1 ICL2 in Coupling G i/s Coupling Promiscuity CB1 signals primarily through the G i /G o family of G proteins but several studies indicate that the receptor can also couple to G s (Felder and Glass, 1998; Glass and Felder, 1997) . Multiple GPCRs have been shown to couple to different G protein subtypes, such as b 2 AR that couples to G s and G i , while some receptors couple almost exclusively to one G protein subtype (e.g., the mOR) (Connor and Christie, 1999) , which couples predominantly to the G i /G o family. While several studies have provided evidence that the mOR may couple to G s in GTPgS binding and cyclic AMP (cAMP) accumulation assays (Chakrabarti et al., 2010; Szü cs et al., 2004) , the coupling is very weak, requiring much higher concentrations of agonist than is needed for G i activation. Earlier work has shown that G s -and G i -coupled receptors appear to have different amino acid preferences at the ICL2 position, with L222 ICL2 , in particular, reported to determine G s protein coupling (Chen et al., 2010) . A L222 ICL2 F mutation in CB1 increased basal signaling through G s , whereas a L222 ICL2 A/L222 ICL2 P mutation led to a loss of G s coupling but retained coupling to G i . In the CB1-G i structure, the ICL2 of the receptor interacts primarily with the a5 helix of G i , but not with the aN-b1 loop as observed in the mOR-G i and b 2 AR-G s complexes.
Notably, L222 ICL2 is only weakly interacting with L194 in the b2-b3 loop of G i (Figure 6E ). The homologous F139 ICL2 in the b2AR is buried in a hydrophobic pocket formed by the a5 helix, the aN-b2 loop, and the b2-b3 loop of G s (Figure 6G ), whereas the corresponding smaller residue V173 ICL2 in the mOR-G i complex is surrounded by a similar hydrophobic pocket formed by I343, F336, and T340 of G i ( Figure 6B ). In contrast, L222 ICL2 of CB1 points toward, but does not engage, the G i hydrophobic pocket ( Figure 6E ). Although alanine substitution of F139 ICL2 in the b 2 AR and other G s coupled receptors impairs their ability to activate G proteins (Moro et al., 1993) , the L222 ICL2 A mutation in CB1 does not alter G i coupling, suggesting that interactions between ICL2 and the hydrophobic pocket are less important for G i coupling of this receptor. On the other hand, the bulkier phenylalanine in the CB1 L222 ICL2 F mutation would be expected to engage the hydrophobic pocket in G s , which has been shown to be required for promoting GDP release.
Figure 7. Structural Changes in G i on CB1 Binding
(A) Comparison of GDP-bound Ga i (PDB: 1GP2, green) and nucleotide-free Ga i from the CB1-G i complex (yellow). The structures are aligned on the b-subunit (CB1-G i , cyan and GDP-bound Ga i , gray). GDP is shown as sticks. The alpha helical domain (AHD) seen in the GDP-bound structure is not resolved in the nucleotide-free Ga i bound to CB1. (B) The a5 helix of Ga i moves upward by 6 Å and rotates $60 to engage the receptor core. The TCAT motif that coordinates the guanosine base of GDP in the GDP-bound structure (green) has shifted upward in the nucleotide-free Ga i bound to mOR (wheat). In CB1-bound Ga i (yellow), the TCAT motif is in a similar position as that seen in A2Abound mini-Ga s (with GDP) (PDB: 5G53, purple). (C) The conformation of the P loop in CB1-bound G i (yellow) will allow nucleotide binding as seen when overlaid with GDP-bound G i (1GP2, smudge). However, in the nucleotide-free G protein bound to mOR (mOR-G i , sand), there is a clash of the P loop with the GDP.
Structural Changes in G i upon Binding CB1
Upon coupling to CB1, the a5 helix of G i undergoes a 6 Å translation and a 60 rotation to engage the core of the receptor (Figures 7A and 7B ). This is in good agreement with other complex structures where the translation of a5 has been shown to influence the position of the b6-a5 loop containing the conserved TCAT motif that directly contacts the guanosine base of GDP. The TCAT motif in G i bound to CB1 has moved $2.0 Å closer to the nucleotide-binding site compared to the recently published mOR-G i structure ( Figure 7C ). Movement of the a5 helix disrupts interactions between its N terminus and the a1 helix, leading to displacement of the P loop ( Figure 7B ) and the destabilization of its contacts GDP, with eventual release of the nucleotide. The P loop in the CB1-G i complex deviates from mOR-G i by 3.5 Å (at E43) but overlays well with the structures of GDP-bound Ga i subunit ( Figure 7C) . Interestingly, the observed P loop conformation in the CB1-G i complex may accommodate nucleotide binding, in contrast to the mOR-G i complex where this is precluded due to potential steric clashes ( Figure 7C ). Thus, while both mOR-G i and CB1-G i complexes are nucleotide-free, the CB1-G i complex may represent a conformation that is poised for GTP binding and activation ( Figure 7C ).
Conclusions
Delineating the structural basis for ligand efficacy and G protein recruitment at CB1 will aid in the design of drugs with high specificity and optimal therapeutic effects. Here, we report a cryo-EM structure of CB1-G i complex revealing the binding mode of the highly potent synthetic cannabinoid FUB and the molecular characteristics of G i protein coupling and activation. FUB binding stabilizes the receptor in an active conformation through interference with the CB1 ''toggle twin switch'' residues F200 3.36 and W356 6.48 . The W356 6.48 repositioning results in the relaxation of the kink at P358 6.50 , thereby allowing the cytoplasmic part of TM6 to straighten and open up to accommodate the C-terminal a5 helix of G i . The rigid C-shape geometry of FUB along with the strong aromatic interactions of its indazole ring with CB1 residues F200 3.36 and W356 6.48 might distinguish this full agonist from partial agonists like D 9 -THC, which has a better safety profile.
Comparison of the CB1-G i complex with the previously determined nucleotide-free structures of mOR-G i, A1A-G i , 5HT1B-G o , rhodopsin-G i , and b 2 AR-G s reveal largely similar overall interaction profiles for receptor-G protein binding. However, compared to the previously determined complex structures, the relative orientation of the CB1 and G i is different, with a weaker interaction between the Ras domain of G i and ICL2 of CB1. Determining G protein coupling specificity has been a major unanswered question in the field of GPCR biology. Although, the CB1-G i complex provides insights into the promiscuous coupling of CB1 relative to CB2, it does not provide a universal molecular basis of G protein coupling specificity across all receptors. It is entirely possible that coupling specificity is determined at the initial stages of complex formation wherein a GDP-bound G protein engages the agonist-activated receptor. However, due to their highly dynamic and transient nature, such pre-equilibrium complexes are currently challenging for structure determination.
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Detailed methods are provided in the online version of this paper and include the following: sodium cholate and 0.05% n-dodecyl-b-D-maltoside (DDM, Anatrace). The heterotrimer containing soluble fraction was purified using Ni-NTA chromatography, and the detergent was exchanged from cholate/DDM to DDM on column. Human rhinovirus 3C protease (3C protease) was added and the histidine tag was cleaved on-column overnight at 4 C. The flow through was collected and was further purified by size exclusion chromatography on Superdex 200 10/300 gel filtration column (GE) into 20 mM HEPES pH 7.5, 100 mM NaCl, 0.02% DDM, 100 mM TCEP, 10 mM GDP, and concentrated to $20 mg/mL for further complexing with the CB1.
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Fluorescence -size exclusion chromatography
Purified CB1-eGFP (1.25 M excess) was incubated with G i (that has been incubated with 1% L-MNG for 1 hour), in the presence of the tested ligands at room temperature for 1 hour, after which apyrase was added and further incubated on ice for 1 hour. The sample was applied to a Superdex 200 10/300 column (equilibrated in 20mM HEPES pH 7.5, 100mM NaCl, 0.01% L-MNG/0.001% CHS) inline with a Jasco FP 2020 Plus fluorescence detector set to an excitation of 480 nm and an emission of 512 nm. Complex formation and complex stability was monitored for each ligand by analyzing the extent of free receptor and complex peaks.
Purification of scFv16 scFv16 was purified as previously described . Briefly, hexahistidine-tagged scFv was expressed in secreted form from Trichuplusia ni Hi5 insect cells using the baculoviral method, and purified by Ni-NTA chromatography. After balancing the pH and quenching chelating agents, the supernatant from baculoviral infected cells was loaded onto Ni-NTA resin. The protein was eluted in 20 mM HEPES pH 7.5, 500 mM NaCl, and 250 mM imidazole and incubated with 3C protease to cleave the carboxy-terminal hexahistidine tag. Following dialysis into a buffer consisting of 20mM HEPES pH 7.5 and 100 mM NaCl, cleaved scFv16 was further purified by reloading over Ni-NTA resin. The flow-through was collected and applied over a Superdex 200 16/60 column. scFv16 fractions were pooled, concentrated, and flash frozen.
CB1-G i complex formation and purification
Purified G i 1 heterotrimer in DDM was incubated with 1% L-MNG for 1 hour at 4 C to exchange the detergent and simultaneously, FUB-bound CB1 was incubated with ZCZ at 24 C. The FUB-and ZCZ-bound CB1 was incubated with a 1.25 molar excess of detergent exchanged G i heterotrimer. The reaction tube was incubated at 24 C for 3 hours and was followed by the addition of apyrase, to stabilize a nucleotide-free complex (Westfield et al., 2011) , for an additional 1.5 hour at 4 C. A 4-fold volume of 20 mM HEPES pH 7.5, 100 mM NaCl, 0.8% L-MNG/0.08% CHS, 0.27% GDN/0.027% CHS, 1 mM MgCl 2 , 10 mM FUB, 1 mM ZCZ and 2 mM CaCl 2 was added to the complexing reaction and purified by M1 anti-FLAG affinity chromatography to remove excess G protein. The complex was eluted in 20mM HEPES pH 7.5, 100mM NaCl, 0.01% L-MNG/0.001% CHS, 0.0033% GDN/0.00033% CHS 10 mM FUB, 1 mM ZCZ, 5 mM EDTA, and FLAG peptide. The eluted complex was supplemented with 100 mM TCEP to provide a reducing environment. A 2 molar excess of scFv16 was added to the preparation and incubated overnight at 4 C. The CB1-G i -scFv16 complex was purified by size exclusion chromatography on a Superdex 200 10/300 Increase column in 20mM HEPES pH 7.5, 100mM NaCl, 10 mM FUB, 1 mM ZCZ, 0.00075% L-MNG/0.000075% CHS and 0.00025% GDN/0.000025% CHS. Peak fractions were concentrated to $16 mg/mL for electron microscopy studies.
Cryo-EM data acquisition
For cryo-EM 3.5 mL of purified CB1-G i complex at 5 mg/ml concentration were applied on glow-discharged holey carbon gold grids (Quantifoil R1.2/1.3, 200 mesh). The grids were blotted using a Vitrobot Mark IV (FEI) with 1 s blotting time at 100% humidity and plunge-frozen in liquid ethane. A total of 2,759 movies were recorded on a Titan Krios electron microscope (Thermo Fisher Scientific -FEI) operating at 300 kV at a calibrated magnification of x29,000 and corresponding to a magnified pixel size of 0.86 Å . Micrographs were recorded using a K2 Summit direct electron camera (Gatan) with a dose rate of $5.0 electrons/Å 2 /s and defocus values ranging from À0.7 mm to À2.5 mm. The total exposure time was 10.0 s and intermediate frames were recorded in 0.2 s intervals resulting in an accumulated dose of $58 electrons per Å 2 and a total of 50 frames per micrograph. Automatic data acquisition was done using SerialEM (Mastronarde, 2005) .
Image processing and 3D reconstructions
Micrographs were subjected to beam-induced motion correction using MotionCor2 (Zheng et al., 2017) . CTF parameters for each micrograph were determined by CTFFIND4 (Rohou and Grigorieff, 2015) . An initial set of 1,178,914 particle projections were extracted using semi-automated procedures and subjected to reference-free two-dimensional classification in RELION 2.1.0 (Fernandez-Leiro and Scheres, 2017). From this step, 562,312 particle projections were selected for further processing. The map of m-opioid receptor (EMDB-7868) low passed filtered to 60 Å was used as an initial reference model for maximum-likelihood-based threedimensional classifications. Conformationally homogeneous groups accounting for 177,787 particles, forming class averages with well resolved features for all subunits, were subjected to 3D masked refinement in Frealign (CisTEM) (Grant et al., 2018) followed by map sharpening applying temperature-factors of À90 Å 2 and À60 Å 2 for the low-and high-resolution ends of the amplitude spectrum, respectively. The final map has an indicated global nominal resolution of 3.0 Å (Figures S1 and S2) . Reported resolution is based on the gold-standard Fourier shell correlation (FSC) using the 0.143 criterion and is in agreement with both Relion 2.1.0 and M-triage as implemented in Phenix (Afonine et al., 2018) . Local resolution was determined using B-soft (Heymann, 2018) with half map reconstructions as input maps ( Figure S2C) .
Model building and refinement
The initial template of CB1 was derived from the crystal structure of agonist-bound CB1 (PDB 5XRA). The m-opioid receptor coordinates (PDB 6DDE) were used as initial models for the G i and scFv16. Agonist coordinates and geometry restrains were generated using phenix.elbow (Moriarty et al., 2009) . Models were docked into the EM density map using UCSF Chimera (Pettersen et al., 2004) , followed by iterative manual building in Coot (Emsley and Cowtan, 2004 ). The final model was subjected to global refinement and minimization in real space using phenix.real_space_refine in Phenix (Adams et al., 2011) . Residues in regions of weak density were stubbed to their Cb position, while preserving sequence information (Stubbed CB1 residues shown in Table S2 ). Molprobity (Williams et al., 2018) was used to evaluate model geometry. FSC curves were calculated between the resulting model and the half map used for refinement as well as between the resulting model and the other half map for cross-validation ( Figure S2 ). The final refinement parameters are provided in Table S1 .
GTP turnover assay Analysis of GTP turnover was performed by using a modified protocol of the GTPase-Glo assay (Promega) described previously (Gregorio et al., 2017) . This assay detects the amount of GTP remaining after GTP hydrolysis, which is enhanced upon activation of the G protein by the ligand-bound receptor. After the GTPase reaction, addition of GTPase-Glo-reagent converts the remaining GTP to ATP that is converted to a luminescent signal by the detection reagent. CB1 was incubated with and without ligands for 30 minutes at room temperature. The reaction was started by mixing the unliganded or liganded-CB1 and G i in an assay buffer containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 0.01% L-MNG, 100 mM TCEP, 10 mM mM GDP and 5 mM GTP. After incubation for 60 minutes (agonists assay) and 30 minutes (for PAM assay), reconstituted GTPase-Glo-reagent was added to the sample and incubated for 30 min at room temperature. Luminescence was measured after the addition of detection reagent and incubation for 10 min at room temperature using a SpectraMax Paradigm plate reader.
Docking and pose refinement
To select ligand poses for simulation, we performed docking with Glide SP (Schrö dinger) against an earlier refinement of the cryo-EM structure (model available upon request). We used the enhanced sampling option to improve conformer generation (set to four times the usual amount of sampling) and requested at most 100 output poses. Subsequent poses were aligned within the electron density map, and two distinct poses that fit within the density were selected for simulation, along with a pose obtained through manual modeling whose orientation also differed from the two Glide-generated poses. In order to compare docking poses for other CB1 agonists, Glide XP docking was performed with CP55,940, D 9 -THC, and the fluoroalkyl analog of FUB.
System setup for MD simulations
Prior to running MD simulations of CB1, we performed several steps of refinement and modeling of the cryo-EM structure. The CB1 model was treated in isolation after removing the G i atoms form the cryo-EM structure. The Advanced Homology Modeling tool in Maestro (Schrö dinger) was used to remodel ECL2 to match the conformation observed in 5XRA. Prime (Schrö dinger) was used to insert missing side chains, hydrogens and cap the termini of the protein while D163 and D213 were manually protonated, in accordance with evidence that these residues become protonated upon GPCR activation (Ghanouni et al., 2000; Ranganathan et al., 2014) . For each of the final candidate ligand poses, the ligand was added to the prepared protein resulting in three unique protein-ligand complexes. Each prepared protein-ligand complex was inserted into a pre-equilibrated palmitoyl oleoylphosphatidylcholine (POPC) bilayer using Dabble (Betz, 2017 ). The final system dimensions were 74.1 3 76.8 3 94.3 Å , including 121 lipids, $10,600 water molecules, 13 sodium ions and 29 chloride ions.
MD simulation force field parameters
The CHARMM36m parameters were used to model protein molecules, CHARMM36 parameters for lipids and salt and the CHARMM36 TIP3P model for water (Huang et al., 2017; Klauda et al., 2010) . Parameters for the ligand were generated using the ParamChem webserver and CGenFF parameterset MD simulation protocol MD simulations were performed on GPUs with the CUDA enabled version of PMEMD in AMBER16 (Case et al., 2008; Salomon-Ferrer et al., 2013) . Each simulation underwent a similar equilibration procedure. Following an initial minimization, each system underwent a heating using the Langevin thermostat from 0K to 100K in the NVT ensemble over 12.5 picoseconds (ps) with 10 kcal mol -1 Å -2 harmonic restraints on all non-hydrogen atoms in the protein, ligand and lipid. The heated then continued in the NPT ensemble with semi-isotropic coupling for 125 ps and a pressure of 1 bar to a final temperature of 310K with 5.0 kcal mol -1 Å -2 harmonic restraints. Further equilibration was then carried out at 310K with harmonic restraints applied to the protein starting at 5.0 kcal mol -1 Å -2 and reduced in a stepwise fashion every 2 ns (ns) for 10 ns, followed by 0.1 kcal mol -1 Å -2 restraints for 20 ns for a total of 30 ns of equilibration. Production simulations were run at 310K and 1 bar in the NPT ensemble using the Langevin thermostat and Monte Carlo barostat. Throughout the final stages of equilibration and production, 5.0 kcal mol -1 Å -2 harmonic restraints were placed on all residues of CB1 that were within 5Å of G i in the CB1-G i complex to ensure that the receptor remained in the active state in the absence of the G-protein.
Each simulation used periodic boundaries and employed a time step of 4.0 fs using hydrogen mass repartitioning (Hopkins et al., 2015) . All bond lengths to hydrogens were constrained by SHAKE (Ryckaert et al., 1977) . Short range electrostatic and van der Waals interactions were cut off at 9.0 Å , while long range electrostatic interactions were computed using the particle mesh Ewald method. The FFT grid size was chosen such that the width of a single grid cell was approximately 1 Å . For each of the three simulated poses, we performed three independent simulations, each of 2.0 ms in length.
Snapshots from each trajectory were saved every 200 ps during the production phase of each simulation and visualized using VMD (Humphrey et al., 1996) . Analysis was carried out using a combination of VMD and locally developed analysis tools.
Quantum Chemical Calculations
Quantum chemical dihedral scans were prepared using the GAUSSIAN software (Frisch et al., 2009 ) for each of the indazole-amide derivatives. All calculations were performed with the uB97-xd functional (Chai and Head-Gordon, 2008 ) and the 6-311++(2d,2p) basis set. The annotated dihedral was scanned in increments of 15 degrees with other degrees of freedom optimized. All compounds had minima at $0 and $180 degrees, the relative energies of which are given in Figure S5 .
Molecular Mechanics JAWS Simulations JAWS simulations (Michel et al., 2009) were prepared from the cryo-EM structure of the CB1 receptor with the MCPRO software package (Jorgensen and Tirado-Rives, 2005) . A 15Å sphere around FUB was solvated with theta waters to be sampled in the simulation and treated as flexible. The protein was simulated with the OPLS-AA/M force field (Robertson et al., 2015) , the ligand used the OPLS-AA/CM1A force field (Udier-Blagovi c et al., 2004) and the TIP4P model was used for the water (Jorgensen et al., 1996) . Simulations used 5 million Monte Carlo steps for solvent equilibration, 10 million Monte Carlo steps in identifying hydration sites, and 50 million Monte Carlo steps in the production phase. Free energies of binding were then calculated from the percentage of the simulation where a given water molecule was predicted to exist, with water molecules sufficiently energetically favorable to always be existent given an energy of > 3.5 kcal/mol.
Figure preparation
Figures were created using PyMol (https://pymol.org/2), and the UCSF Chimera X package (Goddard et al., 2018) .
DATA AND SOFTWARE AVAILABILITY
The cryo-EM density map has been deposited in the Electron Microscopy Data Bank (EMDB) under accession code EMD-0339 and model coordinates have been deposited in the Protein Data Bank (PDB) under accession number 6N4B. Figure S3 . Ligand Binding Pocket and Entry Pathway, Related to Figure 4 (A) A snapshot from MD simulation (yellow) with the N terminus in the most outward position and TM1-TM7 farthest apart compared to the CB1-G i structure (blue).
Supplemental Figures
(B-C) The presence and absence of lipid access channel between TM1 and TM7 in taranabant-and FUB-bound structures respectively. (D) Surface representation of a snapshot from MD simulation showing the ligand access channel between TM1 and TM7. (E) A graph showing the CB1 N terminus (in black) outward movement as measured by the distance observed between the N terminus (Ca F108 N-ter ) and ICL2 (Ca P269 ICL2 ). This N terminus movement coincides with the increase in TM1-TM7 distance (shown in red) distance as measured by (Ca Q116 1.32 ) and ICL2 (Ca T377 7.32 ). The yellow background colors indicate the presence of lipid binding during the simulation. (F) An example of lipid binding the TM1-TM7 gap during MD simulation and the lipid molecule overlaid on the taranabant-bound structure. Figure S4 . Interaction of Agonists with the CB1, Related to Figure 4 (A) FUB assumes a C-shape configuration that occupies most of the binding pocket volume. (B) Docking of FUB analog 5F-MDMB-PINACA (PIN) with a fluoroalkyl moiety to the CB1 binding pocket, with alkyl chain overlapping with the p-fluorobenzyl group in FUB. (C) Docking results of one pose of D 9 -THC (green) superimposed with the structure of FUB (orange) and the crystal structure of AM-11542 (cyan, PDB 5XRA) indicating that the alkyl chain in D 9 -THC overlaps with the p-Fluorobenzyl group and the alkyl chains in FUB and AM-11542, respectively. (D) The docking pose from (C) (light green) superimposed with an alternative docked pose for D 9 -THC (dark green), indicating that the alkyl chain in D 9 -THC fluctuates between two main poses. (E) Chemical structures of FUB, AM-11542 and D 9 -THC, with suggested mechanism for D 9 -THC partial agonism as implemented from the docking experiments. Moieties that interfere with toggle switch activation are highlighted in orange. (F-H) JAWS calculation demonstrating a tightly bound water molecule mediating interactions between FUB (F), H178 2.65 , and S383 7.39 . Both AM-11542 (PDB 5XRA, (G) and CP-55,940 (docked, (H) have hydrogen bonding groups in this region. Chemical structures are showed on bottom, hydrogen bonding group highlighted in light yellow. Comparison of the position of residues at 6.33 and 6.34 in CB1-G i (blue and yellow) and b 2 AR-G s (green and orange) structures.
